Replies to post #247467 on Biotech Values

[vinmantoo]

For now I think ENTA's value is not in hep but in covid and rsv (and the patent suit which is a wild card in all of this)

I agree with you. However, HepB is such a large market and EDP-514 did look pretty good in the one month trial ENTA conducted so I haven't given up hope on it completely.

I don't know anything about ALGS except for what has been recently discussed here so can't add to any discussion about the company or its prospects.